In this article, we will discuss the 13 Best Growth Stocks to Buy Right Now.
On March 16, Chief Investment Strategist at Hightower Stephanie Link and Chief Investment Officer at NFJ Investment Group John Mowrey joined CNBC to discuss oil shocks and market opportunities. Link suggested that while markets may remain in a trading range until there is visibility regarding the Strait of Hormuz, investors should take advantage of current dislocations. She noted that those who sold during Liberation Day missed a 34% rally and advised buying fundamentally strong stocks on weakness.
Mowrey concurred with Link’s opportunistic stance and highlighted potential gains in smaller-cap names that have been disproportionately affected by interest rate concerns. Mowery made a distinction between shock inflation caused by a sudden spike in oil prices and hot inflation driven by a broad economic overheat. He argued that because policymakers are more likely to look through shock inflation, investors should remain bullish, anticipating a significant relief rally once the immediate crisis passes. He notes that while WTI crude briefly crossed $100 per barrel, technology stocks are becoming increasingly attractive as their multiples compress into the low 20s despite CAGR exceeding 30%.
Our Methodology
We used screeners to identify stocks that have a track record of delivering earnings growth and have grown their EPS by at least 20% over the past 3 years. We limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment. These stocks are also popular among analysts and elite hedge funds.
Note: All data was sourced on March 17.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).
13 Best Growth Stocks to Buy Right Now
13. Palisade Bio Inc. (NASDAQ:PALI)
Palisade Bio Inc. (NASDAQ:PALI) is one of the best growth stocks to buy right now. On February 23, Palisade Bio presented translational data from its Phase 1b study of PALI-2108. The findings highlight that this once-daily oral prodrug, designed for targeted delivery to the terminal ileum and colon, achieved localized target engagement and clinical response within 7 days in patients with moderate-to-severe ulcerative colitis.
The data showed a 100% clinical response rate and a 40% clinical remission rate based on modified Mayo Scores, supported by a safety profile across 89 total subjects with no serious adverse events or treatment discontinuations. Mechanism-of-action data derived from colon tissue RNA sequencing confirmed that PALI-2108 successfully suppresses inflammatory and fibrotic gene programs. The results were accompanied by reduced mucosal PDE4B expression, increased tissue cAMP levels, and decreased inflammatory cell signatures. These pharmacologic effects were concentrated in the colonic tissue, while peripheral immune profiles remained largely unchanged, validating the drug’s localized activity.
PALI-2108 uses local bacterial bioactivation to ensure the PDE4 inhibitor remains inactive until it reaches the lower intestine. This targeted approach is engineered to prevent upper gut absorption and minimize peak plasma levels, thereby reducing common systemic side effects such as nausea, headache, and diarrhea. Palisade Bio Inc. (NASDAQ:PALI) believes the convergence of clinical response, tissue pharmacodynamics, and gene expression modulation de-risks the program as PALI-2108 moves into later-stage clinical development.
Palisade Bio Inc. (NASDAQ:PALI) operates as a clinical-stage biopharmaceutical company that develops and advances novel therapeutics for autoimmune, inflammatory, and fibrotic diseases.
12. Blend Labs Inc. (NYSE:BLND)
Blend Labs Inc. (NYSE:BLND) is one of the best growth stocks to buy right now. On March 3, Blend Labs announced the launch of Blend Autopilot, which is an AI agent integrated into its digital origination platform designed to complete loan reviews in as little as 15 seconds. This tool addresses the traditional mortgage cycle, which often spans 30 to 60 days, by reviewing borrower documents and application data in real time.
While the agent automates document parsing, compliance checks, and the generation of follow-up tasks, it remains a non-decisioning tool that leaves all final credit determinations to human underwriters and automated underwriting systems. The technology aims to eliminate the delay between borrower action and lender response, particularly since over half of borrower interactions occur outside of standard business hours.
When a borrower uploads a document or completes an application section, Blend Autopilot immediately cross-references the data against specific lender guidelines and triggers automated workflows. Blend Autopilot is currently available in a preview phase for all Blend platform customers and can be activated via a single toggle in the Lending Config Center without a dedicated implementation project. This agent represents the first in a planned series of AI tools that Blend Labs Inc. (NYSE:BLND) intends to introduce across the entire origination lifecycle.
Blend Labs Inc. (NYSE:BLND) is a technology company that offers a cloud-based software platform for financial services firms. It provides products that power digital-first consumer journeys, such as deposit services and specialized homeownership enhancement tools.
